The Wetherby-based firm hopes to get the test, which works like a pregnancy test but uses saliva, validated before the end of 2020, which could be a game changer for the UK’s testing capability.
Analyst Mark Brewer at FinnCap said: “Avacta is aiming to have validated its rapid SARS-CoV-2 antigen test in the fourth quarter of 2020, the exact timing of which is dependent on pilot batch product from BBI Solutions.
“However, it is increasingly clear that there is a need for mass screening tests to isolate and remove infectious people, with Avacta’s test at the forefront.”
Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.
